Stephan Grupp MD PhD

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Stephan Grupp MD PhD sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 8 currently recruiting early-phase tilt upper quartile by trial count

Stephan Grupp MD PhD: 8 sponsored US clinical trials, 8 recruiting.

Stephan Grupp MD PhD sponsors 8 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is B Lineage Lymphoblastic Lymphoma, with 2 trials.

Upper-quartile sponsor footprint

Stephan Grupp MD PhD sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 1

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

NCT07464951
RECRUITING Phase 2

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

NCT05029336
RECRUITING Phase 1

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

NCT07007117
RECRUITING Phase 1

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

NCT06934382
RECRUITING Phase 1

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

NCT05650749
RECRUITING Phase 1

Co-administration of CART22-65s and huCART19 for B-ALL

NCT05674175
RECRUITING Phase 1

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

NCT05480449
RECRUITING Phase 2

Orphan Indications for CD19 Redirected Autologous T Cells

NCT04276870

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 2

Therapeutic Areas

B Lineage Lymphoblastic Lymphoma 2
Relapsed Neuroblastoma 2
Refractory Neuroblastoma 2
High-risk Neuroblastoma 2
T-Cell Acute Lymphoblastic Leukemia/Lymphoma 1
Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation 1
Infants With Very High Risk KMT2A B-ALL 1
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL 1
Metastatic Retinoblastoma 1
B-cell Acute Lymphoblastic Leukemia (B-ALL) 1

What is open in the Stephan Grupp MD PhD pipeline

8 recruiting of 8 indexed (100% open).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: B Lineage Lymphoblastic Lymphoma (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Stephan Grupp MD PhD: open-pipeline peers nationwide

Peers matched on 8 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Stephan Grupp MD PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0246810 0%50%100%150% Total trials Recruiting share Stephan Grupp MD PhDAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)AAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Stephan Grupp MD PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Stephan Grupp MD PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Stephan Grupp MD PhD page

8 registered trials is a research-attention snapshot, not an endorsement of Stephan Grupp MD PhD or any single study.

  • 8 of Stephan Grupp MD PhD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • B Lineage Lymphoblastic Lymphoma is the condition Stephan Grupp MD PhD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See B Lineage Lymphoblastic Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Stephan Grupp MD PhD pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.